Loading…
Loading…
Pattern recognition, antibody specificity, and clinical decision-making
Autoimmune serology is the cornerstone of rheumatic disease diagnosis, yet interpretation requires understanding of test sensitivity, specificity, and clinical context. At Dr. Shree Narayan's clinic, autoimmune serology interpretation follows a structured approach: ANA screening with pattern recognition (homogeneous, speckled, nucleolar, centromere), confirmation with disease-specific antibodies, and integration with clinical phenotype. A positive ANA in isolation is clinically meaningless — up to 15-25% of healthy individuals have low-titre ANA. The diagnostic value lies in titre magnitude, pattern, and correlation with disease-specific autoantibodies such as anti-dsDNA, anti-Sm, anti-CCP, and anti-Scl-70.
Kathmandu Neurology Clinic & Cognitive Center
Authored and reviewed by Dr. Shree Narayan Yadav (MBBS (KU), MD-Internal Medicine (NAMS), MSc Clinical Rheumatology (USW, UK), NMC 14227). Evidence-based, no fabricated outcomes.
Autoimmune serology is the cornerstone of rheumatic disease diagnosis, yet interpretation requires understanding of test sensitivity, specificity, and clinical context. At Dr. Shree Narayan's clinic, autoimmune serology interpretation follows a structured approach: ANA screening with pattern recognition (homogeneous, speckled, nucleolar, centromere), confirmation with disease-specific antibodies, and integration with clinical phenotype. A positive ANA in isolation is clinically meaningless — up to 15-25% of healthy individuals have low-titre ANA. The diagnostic value lies in titre magnitude, pattern, and correlation with disease-specific autoantibodies such as anti-dsDNA, anti-Sm, anti-CCP, and anti-Scl-70.
Reviewed by Dr. Shree Narayan Yadav, MBBS, MD, MSc — Consultant Physician & Joint and Autoimmune Disease Specialist (NMC 14227), Kathmandu Neurology Clinic. For evaluation, book an appointment.
The antinuclear antibody (ANA) test by indirect immunofluorescence (IIF) on HEp-2 cells is the screening standard with >99% sensitivity for SLE. However, specificity is low (approximately 50-60% at 1:40 titre, improving at >=1:160). The IIF pattern provides diagnostic clues: homogeneous (anti-dsDNA, anti-histone — SLE, drug-induced lupus), speckled (anti-Sm, anti-RNP, anti-SSA/SSB — SLE, Sjogren's, MCTD), nucleolar (anti-RNA polymerase III, anti-PM-Scl — scleroderma), and centromere (anti-centromere — limited cutaneous scleroderma/CREST). The 2019 EULAR/ACR SLE criteria require ANA >=1:80 as entry criterion before applying weighted clinical and immunological criteria.
Beyond ANA, disease-specific autoantibodies dramatically improve diagnostic precision. Anti-dsDNA antibodies are highly specific for SLE (>95%) and correlate with disease activity and lupus nephritis risk. Anti-Sm is the most specific SLE antibody (~99%) but has low sensitivity (20-30%). Anti-CCP (anti-citrullinated protein antibody) is the preferred serological test for rheumatoid arthritis, with specificity of 95-98% compared with 70-80% for rheumatoid factor. Anti-Scl-70 (anti-topoisomerase I) indicates diffuse scleroderma with internal organ involvement, while anti-Jo-1 identifies antisynthetase syndrome.
Complement levels (C3, C4, CH50) are consumed in active immune complex disease and serve as both diagnostic and monitoring markers. Low C3 and C4 in the context of a positive ANA and anti-dsDNA strongly supports active SLE or hypocomplementaemic urticarial vasculitis. Cryoglobulins should be tested when vasculitis, purpura, or neuropathy is present, particularly with concurrent hepatitis C infection. Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, anti-beta-2 glycoprotein I) should be tested at least 12 weeks apart for definitive antiphospholipid syndrome diagnosis per the updated ACR/EULAR 2023 classification criteria.
Fanouriakis A et al. 2019 EULAR/ACR classification criteria for SLE (ANA entry criterion). Ann Rheum DisAringer M et al. EULAR recommendations for the role of autoantibodies in autoimmune diseases. Ann Rheum Dis 2023Barbhaiya M et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis RheumatolContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.